Teva hit with $503 mln EU antitrust fine for disparaging rival product
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 31 2024
0mins
Should l Buy ?
Source: Reuters
Teva's Antitrust Fine: Teva, the world's largest generic drugmaker, has been fined 462.6 million euros by the EU for abusing its dominant position to delay competition for its multiple sclerosis drug, Copaxone, and plans to appeal the ruling.
EU's Stance on Pharmaceutical Practices: The European Commission emphasized its commitment to preventing pharmaceutical companies from using misleading tactics against competitors, as demonstrated by a similar case involving CSL's Vifor Pharma earlier this year.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
